Linda P. Dwoskin - Publications

Affiliations: 
University of Kentucky, Lexington, KY 
Area:
Drug and alcohol abuse
Website:
http://pharmacy.mc.uky.edu/faculty/LindaDwoskin.php

204 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Lee NR, Zheng G, Leggas M, Janganati V, Nickell JR, Crooks PA, Bardo MT, Dwoskin L. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine. The Journal of Pharmacology and Experimental Therapeutics. PMID 31413138 DOI: 10.1124/Jpet.119.258699  0.492
2019 Bardo MT, Denehy ED, Hammerslag LR, Dwoskin LP, Blough BE, Landavazo A, Bergman J, Kohut SJ. Effects of methamphetamine isomers on d-methamphetamine self-administration and food-maintained responding in male rats. Psychopharmacology. PMID 31346628 DOI: 10.1007/S00213-019-05327-8  0.33
2018 Lee NR, Gujarathi S, Bommagani S, Siripurapu K, Zheng G, Dwoskin LP. Muscarinic agonist, (±)-quinuclidin-3-yl-(4-fluorophenethyl)(phenyl)carbamate: High affinity, but low subtype selectivity for human M - M muscarinic acetylcholine receptors. Bioorganic & Medicinal Chemistry Letters. PMID 30554957 DOI: 10.1016/J.Bmcl.2018.12.022  0.38
2018 Maggio SE, Saunders MA, Nixon K, Prendergast MA, Zheng G, Crooks PA, Dwoskin LP, Bell RL, Bardo MT. An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDI. Drug and Alcohol Dependence. 193: 154-161. PMID 30384323 DOI: 10.1016/J.Drugalcdep.2018.09.008  0.618
2018 Maggio SE, Saunders MA, Baxter TA, Nixon K, Prendergast MA, Zheng G, Crooks P, Dwoskin LP, Slack RD, Newman AH, Bell RL, Bardo MT. Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats. Psychopharmacology. PMID 29455292 DOI: 10.1007/S00213-018-4853-4  0.606
2018 Lee NR, Zheng G, Crooks PA, Bardo MT, Dwoskin LP. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders. The Aaps Journal. 20: 29. PMID 29427069 DOI: 10.1208/S12248-018-0192-Y  0.484
2017 Hankosky ER, Joolakanti SR, Nickell JR, Janganati V, Dwoskin LP, Crooks PA. Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorganic & Medicinal Chemistry Letters. PMID 29153425 DOI: 10.1016/J.Bmcl.2017.10.039  0.417
2017 Kangiser MM, Dwoskin LP, Zheng G, Crooks PA, Stairs DJ. Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats. Behavioural Pharmacology. PMID 28863003 DOI: 10.1097/Fbp.0000000000000340  0.372
2017 Marusich JA, Darna M, Wilson AG, Denehy ED, Ebben A, Deaciuc AG, Dwoskin LP, Bardo MT, Lefever TW, Wiley JL, Reissig CJ, Jackson KJ. Tobacco's minor alkaloids: effects on place conditioning and nucleus accumbens dopamine release in adult and adolescent rats. European Journal of Pharmacology. PMID 28844873 DOI: 10.1016/J.Ejphar.2017.08.029  0.473
2017 Baskin BM, Nic Dhonnchadha BÁ, Dwoskin LP, Kantak KM. Blockade of α2-adrenergic receptors in prelimbic cortex: impact on cocaine self-administration in adult spontaneously hypertensive rats following adolescent atomoxetine treatment. Psychopharmacology. PMID 28730282 DOI: 10.1007/S00213-017-4681-Y  0.369
2017 Wilson AG, Lee N, Nickell JR, Culver JP, Janganati V, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. Oral JPC-077, a vesicular monoamine transporter-2 inhibitor, reduces methamphetamine self-administration across repeated treatments Drug and Alcohol Dependence. 171: e218. DOI: 10.1016/J.Drugalcdep.2016.08.595  0.329
2016 Nickell JR, Siripurapu KB, Horton DB, Zheng G, Crooks PA, Dwoskin LP. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. European Journal of Pharmacology. 795: 143-149. PMID 27986625 DOI: 10.1016/J.Ejphar.2016.12.016  0.75
2016 Narayanaswami V, Dwoskin LP. Obesity: Current and Potential Pharmacotherapeutics and Targets. Pharmacology & Therapeutics. PMID 27773782 DOI: 10.1016/J.Pharmthera.2016.10.015  0.601
2016 Charntikov S, Falco AM, Fink K, Dwoskin LP, Bevins RA. The effect of Sazetidine-A and other nicotinic ligands on nicotine controlled goal-tracking in female and male rats. Neuropharmacology. PMID 27765626 DOI: 10.1016/J.Neuropharm.2016.10.014  0.389
2016 Jordan CJ, Lemay C, Dwoskin LP, Kantak KM. Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood. Psychopharmacology. PMID 27600990 DOI: 10.1007/S00213-016-4419-2  0.367
2016 Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA. Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2. Bioorganic & Medicinal Chemistry Letters. PMID 27524311 DOI: 10.1016/J.Bmcl.2016.08.001  0.389
2016 Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA. 1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2. Bioorganic & Medicinal Chemistry Letters. PMID 27212067 DOI: 10.1016/J.Bmcl.2016.05.025  0.428
2016 Joolakanti SR, Nickell JR, Janganati V, Zheng G, Dwoskin LP, Crooks PA. Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorganic & Medicinal Chemistry Letters. PMID 27080180 DOI: 10.1016/J.Bmcl.2016.03.119  0.432
2015 Somkuwar SS, Kantak KM, Bardo MT, Dwoskin LP. Adolescent methylphenidate treatment differentially alters adult impulsivity and hyperactivity in the Spontaneously Hypertensive Rat model of ADHD. Pharmacology, Biochemistry, and Behavior. 141: 66-77. PMID 26657171 DOI: 10.1016/J.Pbb.2015.12.002  0.745
2015 Yates JR, Darna M, Beckmann JS, Dwoskin LP, Bardo MT. Individual differences in impulsive action and dopamine transporter function in rat orbitofrontal cortex. Neuroscience. PMID 26608122 DOI: 10.1016/J.Neuroscience.2015.11.033  0.375
2015 Van Skike CE, Maggio SE, Reynolds AR, Casey EM, Bardo MT, Dwoskin LP, Prendergast MA, Nixon K. Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 26582145 DOI: 10.1016/J.Pnpbp.2015.11.004  0.56
2015 Lee NR, Zhang X, Darna M, Dwoskin LP, Zheng G. Muscarinic acetylcholine receptor binding affinities of pethidine analogs. Bioorganic & Medicinal Chemistry Letters. PMID 26494260 DOI: 10.1016/J.Bmcl.2015.10.029  0.316
2015 Jordan CJ, Taylor DM, Dwoskin LP, Kantak KM. Adolescent d-amphetamine treatment in a rodent model of ADHD: Pro-cognitive effects in adolescence without an impact on cocaine cue reactivity in adulthood. Behavioural Brain Research. 297: 165-179. PMID 26467602 DOI: 10.1016/J.Bbr.2015.10.017  0.359
2015 Beckmann JS, Meyer AC, Pivavarchyk M, Horton DB, Zheng G, Smith AM, Wooters TE, McIntosh JM, Crooks PA, Bardo MT, Dwoskin LP. r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochemical Research. PMID 26227997 DOI: 10.1007/S11064-015-1680-4  0.773
2015 Darna M, Chow JJ, Yates JR, Charnigo RJ, Beckmann JS, Bardo MT, Dwoskin LP. Role of serotonin transporter function in rat orbitofrontal cortex in impulsive choice. Behavioural Brain Research. 293: 134-142. PMID 26183652 DOI: 10.1016/J.Bbr.2015.07.025  0.332
2015 Yates JR, Darna M, Gipson CD, Dwoskin LP, Bardo MT. Dissociable roles of dopamine and serotonin transporter function in a rat model of negative urgency. Behavioural Brain Research. 291: 201-208. PMID 26005123 DOI: 10.1016/J.Bbr.2015.05.023  0.405
2015 Ding D, Nickell JR, Dwoskin LP, Crooks PA. Quinolyl analogues of norlobelane: Novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorganic & Medicinal Chemistry Letters. 25: 2613-6. PMID 25991431 DOI: 10.1016/J.Bmcl.2015.04.105  0.417
2015 Holt JC, Kewin K, Jordan PM, Cameron P, Klapczynski M, McIntosh JM, Crooks PA, Dwoskin LP, Lysakowski A. Pharmacologically distinct nicotinic acetylcholine receptors drive efferent-mediated excitation in calyx-bearing vestibular afferents. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 3625-43. PMID 25716861 DOI: 10.1523/Jneurosci.3388-14.2015  0.331
2015 Somkuwar SS, Kantak KM, Dwoskin LP. Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder. Journal of Neuroscience Methods. PMID 25680322 DOI: 10.1016/J.Jneumeth.2015.02.002  0.738
2015 Baskin BM, Dwoskin LP, Kantak KM. Methylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorder. Pharmacology, Biochemistry, and Behavior. 131: 51-6. PMID 25643872 DOI: 10.1016/J.Pbb.2015.01.019  0.353
2015 Darna M, Beckmann JS, Gipson CD, Bardo MT, Dwoskin LP. Effect of environmental enrichment on dopamine and serotonin transporters and glutamate neurotransmission in medial prefrontal and orbitofrontal cortex. Brain Research. 1599: 115-25. PMID 25536304 DOI: 10.1016/J.Brainres.2014.12.034  0.429
2015 Wilson AG, Nickell J, Culver JP, Janganati V, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. Oral JPC-077 and JPC-141, vesicular monoamine transporter-2 inhibitors, reduce methamphetamine self-administration and methamphetamine-induced reinstatement in rats Drug and Alcohol Dependence. 156: e239. DOI: 10.1016/J.Drugalcdep.2015.07.644  0.359
2015 Jordan CJ, Taylor DM, Jeon S, Baskin BM, Dwoskin LP, Kantak KM. Adolescent d -amphetamine treatment in a rodent model of ADHD: Pro-cognitive effects during adolescence and cocaine abuse risk during adulthood Drug and Alcohol Dependence. 156: e105. DOI: 10.1016/J.Drugalcdep.2015.07.291  0.323
2015 Somkuwar SS, Kantak K, Dwoskin LP. Decreased norepinephrine transporter function in the orbitofrontal cortex and enhanced cocaine abuse risk following adolescent methylphenidate treatment in a rat model of Attention Deficit Hyperactivity Disorder Drug and Alcohol Dependence. 146: e103. DOI: 10.1016/J.Drugalcdep.2014.09.648  0.743
2015 Jordan CJ, Harvey RC, Baskin BM, Rodriguez K, Dellamorte A, Dwoskin LP, Kantak KM. Adolescent atomoxetine, but not methylphenidate, decreases cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder Drug and Alcohol Dependence. 146: e151. DOI: 10.1016/J.Drugalcdep.2014.09.327  0.318
2014 De Biasi M, McLaughlin I, Perez EE, Crooks PA, Dwoskin LP, Bardo MT, Pentel PR, Hatsukami D. Scientific overview: 2013 BBC plenary symposium on tobacco addiction. Drug and Alcohol Dependence. 141: 107-17. PMID 24934691 DOI: 10.1016/J.Drugalcdep.2014.05.013  0.313
2014 Hofford RS, Darna M, Wilmouth CE, Dwoskin LP, Bardo MT. Environmental enrichment reduces methamphetamine cue-induced reinstatement but does not alter methamphetamine reward or VMAT2 function. Behavioural Brain Research. 270: 151-8. PMID 24821405 DOI: 10.1016/J.Bbr.2014.05.007  0.377
2014 Jordan CJ, Harvey RC, Baskin BB, Dwoskin LP, Kantak KM. Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments. Drug and Alcohol Dependence. 140: 25-32. PMID 24811203 DOI: 10.1016/J.Drugalcdep.2014.04.020  0.35
2014 Gauthier JM, Tassin DH, Dwoskin LP, Kantak KM. Effects of dopamine D1 receptor blockade in the prelimbic prefrontal cortex or lateral dorsal striatum on frontostriatal function in Wistar and Spontaneously Hypertensive Rats. Behavioural Brain Research. 268: 229-38. PMID 24755309 DOI: 10.1016/J.Bbr.2014.04.018  0.403
2014 Crooks PA, Bardo MT, Dwoskin LP. Nicotinic receptor antagonists as treatments for nicotine abuse. Advances in Pharmacology (San Diego, Calif.). 69: 513-51. PMID 24484986 DOI: 10.1016/B978-0-12-420118-7.00013-5  0.502
2014 Nickell JR, Siripurapu KB, Vartak A, Crooks PA, Dwoskin LP. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Advances in Pharmacology (San Diego, Calif.). 69: 71-106. PMID 24484975 DOI: 10.1016/B978-0-12-420118-7.00002-0  0.513
2014 Nickell JR, Beckmann J, Denehy E, Siripurapu K, Culver J, Bardo M, Crooks P, Dwoskin LP. Preclinical evaluation of JPC-077 as a novel treatment for methamphetamine abuse Drug and Alcohol Dependence. 140: e160-e161. DOI: 10.1016/J.Drugalcdep.2014.02.453  0.386
2014 Darna M, Yates JR, Bardo M, Dwoskin LP. Individual differences in negative urgency behavior: Relationship with dopamine transporter function Drug and Alcohol Dependence. 140: e43. DOI: 10.1016/J.Drugalcdep.2014.02.139  0.354
2013 Wilmouth CE, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. Pharmacology, Biochemistry, and Behavior. 112: 29-33. PMID 24075974 DOI: 10.1016/J.Pbb.2013.09.006  0.326
2013 Ding D, Nickell JR, Deaciuc AG, Penthala NR, Dwoskin LP, Crooks PA. Synthesis and evaluation of novel azetidine analogs as potent inhibitors of vesicular [3H]dopamine uptake. Bioorganic & Medicinal Chemistry. 21: 6771-7. PMID 23993667 DOI: 10.1016/J.Bmc.2013.08.001  0.356
2013 Martin CA, Nuzzo PA, Ranseen JD, Kleven MS, Guenthner G, Williams Y, Walsh SL, Dwoskin LP. Lobeline Effects on Cognitive Performance in Adult ADHD. Journal of Attention Disorders. PMID 23966351 DOI: 10.1177/1087054713497791  0.767
2013 Meyer AC, Neugebauer NM, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo. Journal of Neurochemistry. 127: 187-98. PMID 23875705 DOI: 10.1111/Jnc.12373  0.411
2013 Horton DB, Nickell JR, Zheng G, Crooks PA, Dwoskin LP. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine. Journal of Neurochemistry. 127: 177-86. PMID 23875622 DOI: 10.1111/Jnc.12371  0.744
2013 Narayanaswami V, Somkuwar SS, Horton DB, Cassis LA, Dwoskin LP. Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [³H]dopamine and [³H]norepinephrine release. Biochemical Pharmacology. 86: 656-65. PMID 23831951 DOI: 10.1016/J.Bcp.2013.06.025  0.821
2013 Somkuwar SS, Jordan CJ, Kantak KM, Dwoskin LP. Adolescent atomoxetine treatment in a rodent model of ADHD: effects on cocaine self-administration and dopamine transporters in frontostriatal regions. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 2588-97. PMID 23822950 DOI: 10.1038/Npp.2013.163  0.752
2013 Somkuwar SS, Darna M, Kantak KM, Dwoskin LP. Adolescence methylphenidate treatment in a rodent model of attention deficit/hyperactivity disorder: dopamine transporter function and cellular distribution in adulthood. Biochemical Pharmacology. 86: 309-16. PMID 23623751 DOI: 10.1016/J.Bcp.2013.04.013  0.758
2013 Nickell JR, Grinevich VP, Siripurapu KB, Smith AM, Dwoskin LP. Potential therapeutic uses of mecamylamine and its stereoisomers. Pharmacology, Biochemistry, and Behavior. 108: 28-43. PMID 23603417 DOI: 10.1016/J.Pbb.2013.04.005  0.409
2013 Penthala NR, Ponugoti PR, Nickell JR, Deaciuc AG, Dwoskin LP, Crooks PA. Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2). Bioorganic & Medicinal Chemistry Letters. 23: 3342-5. PMID 23597792 DOI: 10.1016/J.Bmcl.2013.03.092  0.372
2013 Zheng G, Horton DB, Penthala NR, Nickell JR, Culver JP, Deaciuc AG, Dwoskin LP, Crooks PA. Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse. Medchemcomm. 4: 564-568. PMID 23527317 DOI: 10.1039/C3Md20374C  0.737
2013 Zheng G, Smith AM, Huang X, Subramanian KL, Siripurapu KB, Deaciuc A, Zhan CG, Dwoskin LP. Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists. Journal of Medicinal Chemistry. 56: 1693-703. PMID 23379472 DOI: 10.1021/Jm301774U  0.352
2013 Narayanaswami V, Thompson AC, Cassis LA, Bardo MT, Dwoskin LP. Diet-induced obesity: dopamine transporter function, impulsivity and motivation. International Journal of Obesity (2005). 37: 1095-103. PMID 23164701 DOI: 10.1038/Ijo.2012.178  0.695
2013 Zhu J, Bardo MT, Dwoskin LP. Distinct effects of enriched environment on dopamine clearance in nucleus accumbens shell and core following systemic nicotine administration. Synapse (New York, N.Y.). 67: 57-67. PMID 23065942 DOI: 10.1002/Syn.21615  0.549
2013 Dwoskin LP, Somkuwar SS, Jordan C, Harvey R, Bardo M, Kantak K. C.10 - METHYLPHENIDATE AND ATOMOXETINE TREATMENT IN THE SPONTANEOUSLY HYPERTENSIVE RAT MODEL OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER Behavioural Pharmacology. 24: e33. DOI: 10.1097/01.Fbp.0000434794.64301.8F  0.72
2012 Alvers KM, Beckmann JS, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology. 224: 255-62. PMID 22638813 DOI: 10.1007/S00213-012-2748-3  0.314
2012 Yates JR, Darna M, Gipson CD, Dwoskin LP, Bardo MT. Isolation rearing as a preclinical model of attention/deficit-hyperactivity disorder. Behavioural Brain Research. 234: 292-8. PMID 22580232 DOI: 10.1016/J.Bbr.2012.04.043  0.399
2012 Theodore S, Cass WA, Dwoskin LP, Maragos WF. HIV-1 protein Tat inhibits vesicular monoamine transporter-2 activity in rat striatum. Synapse (New York, N.Y.). 66: 755-7. PMID 22517264 DOI: 10.1002/Syn.21564  0.671
2012 Smith AM, Wellmann KA, Lundblad TM, Carter ML, Barron S, Dwoskin LP. Lobeline attenuates neonatal ethanol-mediated changes in hyperactivity and dopamine transporter function in the prefrontal cortex in rats. Neuroscience. 206: 245-54. PMID 22119644 DOI: 10.1016/J.Neuroscience.2011.11.018  0.363
2012 Beckmann JS, Denehy ED, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology. 220: 395-403. PMID 21938414 DOI: 10.1007/S00213-011-2488-9  0.341
2011 Holtman JR, Dwoskin LP, Dowell C, Wala EP, Zhang Z, Crooks PA, McIntosh JM. The novel small molecule α9α10 nicotinic acetylcholine receptor antagonist ZZ-204G is analgesic. European Journal of Pharmacology. 670: 500-8. PMID 21944926 DOI: 10.1016/J.Ejphar.2011.08.053  0.382
2011 Wooters TE, Dwoskin LP, Bardo MT. Discriminative stimulus effects of NMDA, AMPA, and mGluR5 glutamate receptor ligands in methamphetamine-trained rats. Behavioural Pharmacology. 22: 516-24. PMID 21836462 DOI: 10.1097/Fbp.0B013E328349Aafa  0.308
2011 Horton DB, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. The Journal of Pharmacology and Experimental Therapeutics. 339: 286-97. PMID 21778282 DOI: 10.1124/Jpet.111.184770  0.756
2011 Meyer AC, Horton DB, Neugebauer NM, Wooters TE, Nickell JR, Dwoskin LP, Bardo MT. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration. Neuropharmacology. 61: 849-56. PMID 21669212 DOI: 10.1016/J.Neuropharm.2011.05.033  0.746
2011 Marusich JA, Darna M, Charnigo RJ, Dwoskin LP, Bardo MT. A multivariate assessment of individual differences in sensation seeking and impulsivity as predictors of amphetamine self-administration and prefrontal dopamine function in rats. Experimental and Clinical Psychopharmacology. 19: 275-84. PMID 21574722 DOI: 10.1037/A0023897  0.348
2011 Zheng G, Zhang Z, Dowell C, Wala E, Dwoskin LP, Holtman JR, McIntosh JM, Crooks PA. Discovery of non-peptide, small molecule antagonists of α9α10 nicotinic acetylcholine receptors as novel analgesics for the treatment of neuropathic and tonic inflammatory pain. Bioorganic & Medicinal Chemistry Letters. 21: 2476-9. PMID 21397497 DOI: 10.1016/J.Bmcl.2011.02.043  0.387
2011 Pivavarchyk M, Smith AM, Zhang Z, Zhou D, Wang X, Toyooka N, Tsuneki H, Sasaoka T, McIntosh JM, Crooks PA, Dwoskin LP. Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release. European Journal of Pharmacology. 658: 132-9. PMID 21371454 DOI: 10.1016/J.Ejphar.2011.02.018  0.507
2011 Wooters TE, Smith AM, Pivavarchyk M, Siripurapu KB, McIntosh JM, Zhang Z, Crooks PA, Bardo MT, Dwoskin LP. bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. British Journal of Pharmacology. 163: 346-57. PMID 21232049 DOI: 10.1111/J.1476-5381.2011.01220.X  0.533
2011 Wooters TE, Bardo MT, Dwoskin LP, Midde NM, Gomez AM, Mactutus CF, Booze RM, Zhu J. Effect of environmental enrichment on methylphenidate-induced locomotion and dopamine transporter dynamics. Behavioural Brain Research. 219: 98-107. PMID 21219939 DOI: 10.1016/J.Bbr.2011.01.001  0.808
2011 Horton DB, Siripurapu KB, Norrholm SD, Culver JP, Hojahmat M, Beckmann JS, Harrod SB, Deaciuc AG, Bardo MT, Crooks PA, Dwoskin LP. meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. The Journal of Pharmacology and Experimental Therapeutics. 336: 940-51. PMID 21177475 DOI: 10.1124/Jpet.110.175117  0.826
2011 Zhang Z, Zheng G, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Novel bis-, tris-, and tetrakis-tertiary amino analogs as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release. Bioorganic & Medicinal Chemistry Letters. 21: 88-91. PMID 21147530 DOI: 10.1016/J.Bmcl.2010.11.070  0.52
2011 Crooks PA, Zheng G, Vartak AP, Culver JP, Zheng F, Horton DB, Dwoskin LP. Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Current Topics in Medicinal Chemistry. 11: 1103-27. PMID 21050177 DOI: 10.2174/156802611795371332  0.747
2011 Nickell JR, Zheng G, Deaciuc AG, Crooks PA, Dwoskin LP. Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2. The Journal of Pharmacology and Experimental Therapeutics. 336: 724-33. PMID 20876747 DOI: 10.1124/Jpet.110.172882  0.457
2011 Perry JL, Joseph JE, Jiang Y, Zimmerman RS, Kelly TH, Darna M, Huettl P, Dwoskin LP, Bardo MT. Prefrontal cortex and drug abuse vulnerability: translation to prevention and treatment interventions. Brain Research Reviews. 65: 124-49. PMID 20837060 DOI: 10.1016/J.Brainresrev.2010.09.001  0.302
2010 Smith AM, Dwoskin LP, Pauly JR. Early exposure to nicotine during critical periods of brain development: Mechanisms and consequences. Journal of Pediatric Biochemistry. 1: 125-141. PMID 24904708 DOI: 10.3233/Jpb-2010-0012  0.418
2010 Beckmann JS, Siripurapu KB, Nickell JR, Horton DB, Denehy ED, Vartak A, Crooks PA, Dwoskin LP, Bardo MT. The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. The Journal of Pharmacology and Experimental Therapeutics. 335: 841-51. PMID 20805303 DOI: 10.1124/Jpet.110.172742  0.783
2010 Meyer AC, Rahman S, Charnigo RJ, Dwoskin LP, Crabbe JC, Bardo MT. Genetics of novelty seeking, amphetamine self-administration and reinstatement using inbred rats. Genes, Brain, and Behavior. 9: 790-8. PMID 20618445 DOI: 10.1111/J.1601-183X.2010.00616.X  0.332
2010 Smith AM, Pivavarchyk M, Wooters TE, Zhang Z, Zheng G, McIntosh JM, Crooks PA, Bardo MT, Dwoskin LP. Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochemical Pharmacology. 80: 402-9. PMID 20346923 DOI: 10.1016/J.Bcp.2010.03.018  0.511
2010 Zhang Z, Pivavarchyk M, Subramanian KL, Deaciuc AG, Dwoskin LP, Crooks PA. Novel bis-2,2,6,6-tetramethylpiperidine (bis-TMP) and bis-mecamylamine antagonists at neuronal nicotinic receptors mediating nicotine-evoked dopamine release. Bioorganic & Medicinal Chemistry Letters. 20: 1420-3. PMID 20079634 DOI: 10.1016/J.Bmcl.2009.12.089  0.52
2010 Geldenhuys WJ, Manda VK, Mittapalli RK, Van der Schyf CJ, Crooks PA, Dwoskin LP, Allen DD, Lockman PR. Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter. Bioorganic & Medicinal Chemistry Letters. 20: 870-7. PMID 20053562 DOI: 10.1016/J.Bmcl.2009.12.079  0.397
2010 Hojahmat M, Horton DB, Norrholm SD, Miller DK, Grinevich VP, Deaciuc AG, Dwoskin LP, Crooks PA. Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters. Bioorganic & Medicinal Chemistry. 18: 640-9. PMID 20036131 DOI: 10.1016/J.Bmc.2009.12.002  0.798
2010 Nickell JR, Krishnamurthy S, Norrholm S, Deaciuc G, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. The Journal of Pharmacology and Experimental Therapeutics. 332: 612-21. PMID 19855096 DOI: 10.1124/Jpet.109.160275  0.707
2010 Holtman J, Dwoskin L, Wala E, Crooks P, McIntosch J. Novel small molecule alpha9 alpha10 nicotinic receptor antagonists for pain management The Journal of Pain. 11: S33. DOI: 10.1016/J.Jpain.2010.01.138  0.309
2009 Zheng G, Dwoskin LP, Deaciuc AG, Crooks PA. Stereocontrolled synthesis and pharmacological evaluation of cis-2,6-diphenethyl-1-azabicyclo[2.2.2]octanes as lobelane analogues. The Journal of Organic Chemistry. 74: 6072-6. PMID 20560567 DOI: 10.1021/Jo901082R  0.317
2009 Struthers AM, Wilkinson JL, Dwoskin LP, Crooks PA, Bevins RA. Mecamylamine, dihydro-beta-erythroidine, and dextromethorphan block conditioned responding evoked by the conditional stimulus effects of nicotine. Pharmacology, Biochemistry, and Behavior. 94: 319-28. PMID 19778551 DOI: 10.1016/J.Pbb.2009.09.012  0.42
2009 Vartak AP, Nickell JR, Chagkutip J, Dwoskin LP, Crooks PA. Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2). Journal of Medicinal Chemistry. 52: 7878-82. PMID 19691331 DOI: 10.1021/Jm900770H  0.311
2009 Smith AM, Dhawan GK, Zhang Z, Siripurapu KB, Crooks PA, Dwoskin LP. The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices. Biochemical Pharmacology. 78: 889-97. PMID 19631612 DOI: 10.1016/J.Bcp.2009.07.010  0.51
2009 López-Hernández GY, Thinschmidt JS, Zheng G, Zhang Z, Crooks PA, Dwoskin LP, Papke RL. Selective inhibition of acetylcholine-evoked responses of alpha7 neuronal nicotinic acetylcholine receptors by novel tris- and tetrakis-azaaromatic quaternary ammonium antagonists. Molecular Pharmacology. 76: 652-66. PMID 19556356 DOI: 10.1124/Mol.109.056176  0.404
2009 Dwoskin LP, Smith AM, Wooters TE, Zhang Z, Crooks PA, Bardo MT. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochemical Pharmacology. 78: 732-43. PMID 19523455 DOI: 10.1016/J.Bcp.2009.06.002  0.467
2009 Zheng F, McConnell MJ, Zhan CG, Dwoskin LP, Crooks PA. QSAR study on maximal inhibition (Imax) of quaternary ammonium antagonists for S-(-)-nicotine-evoked dopamine release from dopaminergic nerve terminals in rat striatum. Bioorganic & Medicinal Chemistry. 17: 4477-85. PMID 19477134 DOI: 10.1016/J.Bmc.2009.05.010  0.497
2009 Zhu J, Apparsundaram S, Dwoskin LP. Nicotinic receptor activation increases [3H]dopamine uptake and cell surface expression of dopamine transporters in rat prefrontal cortex. The Journal of Pharmacology and Experimental Therapeutics. 328: 931-9. PMID 19088301 DOI: 10.1124/Jpet.108.147025  0.57
2009 Dwoskin LP, Bardo MT. Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 244-6. PMID 19079069 DOI: 10.1038/Npp.2008.157  0.402
2009 Dwoskin LP, Pivavarchyk M, Joyce BM, Neugebauer NM, Zheng G, Zhang Z, Bardo MT, Crooks PA. Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebraska Symposium On Motivation. Nebraska Symposium On Motivation. 55: 31-63. PMID 19013938 DOI: 10.1007/978-0-387-78748-0_4  0.388
2009 Zheng F, Zheng G, Deaciuc AG, Zhan CG, Dwoskin LP, Crooks PA. Computational neural network analysis of the affinity of N-n-alkylnicotinium salts for the alpha4beta2* nicotinic acetylcholine receptor. Journal of Enzyme Inhibition and Medicinal Chemistry. 24: 157-68. PMID 18629679 DOI: 10.1080/14756360801945648  0.329
2009 McIntosh J, Dwoskin L, Crooks P, Holtman J. GZ556A and ZZ204G are novel small molecule antagonists of α9α10 nAChRs and are analgesic in rats Biochemical Pharmacology. 78: 921. DOI: 10.1016/J.Bcp.2009.06.084  0.353
2008 Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. The novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens. European Journal of Pharmacology. 601: 103-5. PMID 19000671 DOI: 10.1016/J.Ejphar.2008.10.037  0.507
2008 Zheng G, Dwoskin LP, Deaciuc AG, Crooks PA. Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2. Bioorganic & Medicinal Chemistry Letters. 18: 6509-12. PMID 18976906 DOI: 10.1016/J.Bmcl.2008.10.042  0.324
2008 Zhang Z, Zheng G, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Tetrakis-azaaromatic quaternary ammonium salts: novel subtype-selective antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release. Bioorganic & Medicinal Chemistry Letters. 18: 5753-7. PMID 18851914 DOI: 10.1016/J.Bmcl.2008.09.084  0.475
2008 Zhang Z, Lockman PR, Mittapalli RK, Allen DD, Dwoskin LP, Crooks PA. bis-Pyridinium cyclophanes: novel ligands with high affinity for the blood-brain barrier choline transporter. Bioorganic & Medicinal Chemistry Letters. 18: 5622-5. PMID 18793853 DOI: 10.1016/J.Bmcl.2008.08.099  0.334
2008 Albayati ZA, Dwoskin LP, Crooks PA. Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 2024-9. PMID 18617603 DOI: 10.1124/Dmd.108.020354  0.316
2008 Dwoskin LP, Wooters TE, Sumithran SP, Siripurapu KB, Joyce BM, Lockman PR, Manda VK, Ayers JT, Zhang Z, Deaciuc AG, McIntosh JM, Crooks PA, Bardo MT. N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. The Journal of Pharmacology and Experimental Therapeutics. 326: 563-76. PMID 18460644 DOI: 10.1124/Jpet.108.136630  0.528
2008 Papke RL, Dwoskin LP, Crooks PA, Zheng G, Zhang Z, McIntosh JM, Stokes C. Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras. Neuropharmacology. 54: 1189-200. PMID 18448138 DOI: 10.1016/J.Neuropharm.2008.03.010  0.327
2008 Rahman S, Zhang Z, Papke RL, Crooks PA, Dwoskin LP, Bardo MT. Region-specific effects of N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo. British Journal of Pharmacology. 153: 792-804. PMID 18059317 DOI: 10.1038/Sj.Bjp.0707612  0.532
2008 Lockman PR, Manda VK, Geldenhuys WJ, Mittapalli RK, Thomas F, Albayati ZF, Crooks PA, Dwoskin LP, Allen DD. Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist n,n'-dodecylbispicolinium dibromide at the blood-brain barrier. The Journal of Pharmacology and Experimental Therapeutics. 324: 244-50. PMID 17921191 DOI: 10.1124/Jpet.107.130906  0.436
2007 Zheng G, Zhang Z, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation. Bioorganic & Medicinal Chemistry Letters. 17: 6734-8. PMID 18029180 DOI: 10.1016/J.Bmcl.2007.10.052  0.511
2007 Norrholm SD, Horton DB, Dwoskin LP. The promiscuity of the dopamine transporter: implications for the kinetic analysis of [3H]serotonin uptake in rat hippocampal and striatal synaptosomes. Neuropharmacology. 53: 982-9. PMID 18022203 DOI: 10.1016/J.Neuropharm.2007.10.001  0.792
2007 Zheng G, Sumithran SP, Deaciuc AG, Dwoskin LP, Crooks PA. Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorganic & Medicinal Chemistry Letters. 17: 6701-6. PMID 17977723 DOI: 10.1016/J.Bmcl.2007.10.062  0.535
2007 Zhu J, Bardo MT, Green TA, Wedlund PJ, Dwoskin LP. Nicotine increases dopamine clearance in medial prefrontal cortex in rats raised in an enriched environment. Journal of Neurochemistry. 103: 2575-88. PMID 17953677 DOI: 10.1111/J.1471-4159.2007.04951.X  0.544
2007 Dwoskin LP, Joyce BM, Zheng G, Neugebauer NM, Manda VK, Lockman P, Papke RL, Bardo MT, Crooks PA. Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD). Biochemical Pharmacology. 74: 1271-82. PMID 17727820 DOI: 10.1016/J.Bcp.2007.07.021  0.526
2007 Zhu J, Bardo MT, Bruntz RC, Stairs DJ, Dwoskin LP. Individual differences in response to novelty predict prefrontal cortex dopamine transporter function and cell surface expression. The European Journal of Neuroscience. 26: 717-28. PMID 17651428 DOI: 10.1111/J.1460-9568.2007.05690.X  0.53
2007 Neugebauer NM, Harrod SB, Stairs DJ, Crooks PA, Dwoskin LP, Bardo MT. Lobelane decreases methamphetamine self-administration in rats. European Journal of Pharmacology. 571: 33-8. PMID 17612524 DOI: 10.1016/J.Ejphar.2007.06.003  0.369
2007 Papke RL, Dwoskin LP, Crooks PA. The pharmacological activity of nicotine and nornicotine on nAChRs subtypes: relevance to nicotine dependence and drug discovery. Journal of Neurochemistry. 101: 160-7. PMID 17241116 DOI: 10.1111/J.1471-4159.2006.04355.X  0.424
2007 Middleton LS, Crooks PA, Wedlund PJ, Cass WA, Dwoskin LP. Nornicotine inhibition of dopamine transporter function in striatum via nicotinic receptor activation. Synapse (New York, N.Y.). 61: 157-65. PMID 17146768 DOI: 10.1002/Syn.20351  0.749
2007 Middleton LS, Apparsundaram S, King-Pospisil KA, Dwoskin LP. Nicotine increases dopamine transporter function in rat striatum through a trafficking-independent mechanism. European Journal of Pharmacology. 554: 128-36. PMID 17141211 DOI: 10.1016/J.Ejphar.2006.09.074  0.523
2007 Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology. 52: 755-63. PMID 17097117 DOI: 10.1016/J.Neuropharm.2006.09.012  0.513
2007 Stairs DJ, Neugebauer NM, Wei X, Boustany C, Hojahmat M, Cassis LA, Crooks PA, Dwoskin LP, Bardo MT. Effects of nornicotine enantiomers on intravenous S(-)-nicotine self-administration and cardiovascular function in rats. Psychopharmacology. 190: 145-55. PMID 17096082 DOI: 10.1007/S00213-006-0610-1  0.407
2007 Bardo MT, Williams Y, Dwoskin LP, Moynahan SE, Perry IB, Martin CA. The sensation seeking trait and substance use: Research findings and clinical implications Current Psychiatry Reviews. 3: 3-13. DOI: 10.2174/157340007779815682  0.778
2006 Chen J, Deaciuc AG, Dwoskin LP, Crooks PA, Bai D. N, N -disubstituted piperazines and homopiperazines: synthesis and affinities at alpha4beta2* and alpha7* neuronal nicotinic acetylcholine receptors. Journal of Enzyme Inhibition and Medicinal Chemistry. 21: 667-80. PMID 17252939 DOI: 10.1080/14756360600900513  0.392
2006 Zheng G, Dwoskin LP, Crooks PA. Vesicular monoamine transporter 2: role as a novel target for drug development. The Aaps Journal. 8: E682-92. PMID 17233532 DOI: 10.1208/Aapsj080478  0.382
2006 Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. Cns Drug Reviews. 12: 178-207. PMID 17227286 DOI: 10.1111/J.1527-3458.2006.00178.X  0.49
2006 Huang X, Zheng F, Chen X, Crooks PA, Dwoskin LP, Zhan CG. Modeling subtype-selective agonists binding with alpha4beta2 and alpha7 nicotinic acetylcholine receptors: effects of local binding and long-range electrostatic interactions. Journal of Medicinal Chemistry. 49: 7661-74. PMID 17181149 DOI: 10.1021/Jm0606701  0.365
2006 Zheng G, Horton DB, Deaciuc AG, Dwoskin LP, Crooks PA. Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorganic & Medicinal Chemistry Letters. 16: 5018-21. PMID 16905316 DOI: 10.1016/J.Bmcl.2006.07.070  0.757
2006 Wooters TE, Dwoskin LP, Bardo MT. Age and sex differences in the locomotor effect of repeated methylphenidate in rats classified as high or low novelty responders. Psychopharmacology. 188: 18-27. PMID 16896959 DOI: 10.1007/S00213-006-0445-9  0.329
2006 Zheng F, Bayram E, Sumithran SP, Ayers JT, Zhan CG, Schmitt JD, Dwoskin LP, Crooks PA. QSAR modeling of mono- and bis-quaternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating dopamine release. Bioorganic & Medicinal Chemistry. 14: 3017-37. PMID 16431111 DOI: 10.1016/J.Bmc.2005.12.036  0.396
2006 Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats. Psychopharmacology. 184: 426-34. PMID 16220336 DOI: 10.1007/S00213-005-0163-8  0.478
2005 Wilkins LH, Miller DK, Ayers JT, Crooks PA, Dwoskin LP. N-n-alkylnicotinium analogs, a novel class of antagonists at alpha 4 beta 2* nicotinic acetylcholine receptors: inhibition of S(-)-nicotine-evoked 86Rb+ efflux from rat thalamic synaptosomes. The Aaps Journal. 7: E922-30. PMID 16594645 DOI: 10.1208/Aapsj070490  0.782
2005 Ayers JT, Xu R, Dwoskin LP, Crooks PA. A general procedure for the enantioselective synthesis of the minor tobacco alkaloids nornicotine, anabasine, and anatabine. The Aaps Journal. 7: E752-8. PMID 16353951 DOI: 10.1208/Aapsj070375  0.324
2005 Ayers JT, Clauset A, Schmitt JD, Dwoskin LP, Crooks PA. Molecular modeling of mono- and bis-quaternary ammonium salts as ligands at the alpha4beta2 nicotinic acetylcholine receptor subtype using nonlinear techniques. The Aaps Journal. 7: E678-85. PMID 16353944 DOI: 10.1208/Aapsj070368  0.347
2005 Rauhut AS, Dwoskin LP, Bardo MT. Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 7: 901-7. PMID 16298725 DOI: 10.1080/14622200500381384  0.405
2005 Huang X, Zheng F, Crooks PA, Dwoskin LP, Zhan CG. Modeling multiple species of nicotine and deschloroepibatidine interacting with alpha4beta2 nicotinic acetylcholine receptor: from microscopic binding to phenomenological binding affinity. Journal of the American Chemical Society. 127: 14401-14. PMID 16218635 DOI: 10.1021/Ja052681+  0.353
2005 Wei X, Sumithran SP, Deaciuc AG, Burton HR, Bush LP, Dwoskin LP, Crooks PA. Identification and synthesis of novel alkaloids from the root system of Nicotiana tabacum: affinity for neuronal nicotinic acetylcholine receptors. Life Sciences. 78: 495-505. PMID 16197964 DOI: 10.1016/J.Lfs.2005.09.009  0.496
2005 Sumithran SP, Crooks PA, Xu R, Zhu J, Deaciuc AG, Wilkins LH, Dwoskin LP. Introduction of unsaturation into the N-n-alkyl chain of the nicotinic receptor antagonists, NONI and NDNI: effect on affinity and selectivity. The Aaps Journal. 7: E201-17. PMID 16146341 DOI: 10.1208/Aapsj070119  0.811
2005 Zheng G, Dwoskin LP, Deaciuc AG, Crooks PA. Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands. Bioorganic & Medicinal Chemistry Letters. 15: 4463-6. PMID 16112864 DOI: 10.1016/J.Bmcl.2005.07.032  0.397
2005 Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, Crooks PA. Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. Journal of Medicinal Chemistry. 48: 5551-60. PMID 16107155 DOI: 10.1021/Jm0501228  0.679
2005 Papke RL, Zheng G, Horenstein NA, Dwoskin LP, Crooks PA. The characterization of a novel rigid nicotine analog with alpha7-selective nAChR agonist activity and modulation of agonist properties by boron inclusion. Bioorganic & Medicinal Chemistry Letters. 15: 3874-80. PMID 16005216 DOI: 10.1016/J.Bmcl.2005.05.118  0.386
2005 Zhu J, Apparsundaram S, Bardo MT, Dwoskin LP. Environmental enrichment decreases cell surface expression of the dopamine transporter in rat medial prefrontal cortex. Journal of Neurochemistry. 93: 1434-43. PMID 15935059 DOI: 10.1111/J.1471-4159.2005.03130.X  0.487
2005 Zheng G, Dwoskin LP, Deaciuc AG, Zhu J, Jones MD, Crooks PA. Lobelane analogues as novel ligands for the vesicular monoamine transporter-2. Bioorganic & Medicinal Chemistry. 13: 3899-909. PMID 15911306 DOI: 10.1016/J.Bmc.2005.04.013  0.359
2005 Geldenhuys WJ, Lockman PR, Nguyen TH, Van der Schyf CJ, Crooks PA, Dwoskin LP, Allen DD. 3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter. Bioorganic & Medicinal Chemistry. 13: 4253-61. PMID 15878282 DOI: 10.1016/J.Bmc.2005.04.020  0.32
2005 Dwoskin L, Zhu J, Cain M, Bardo M. A108 INDIVIDUAL DIFFERENCES IN NICOTINE-INDUCED HYPERACTIVITY AND NICOTINE-INDUCED AUGMENTATION OF DOPAMINE TRANSPORTER FUNCTION AND TRAFFICKING TO THE CELL SURFACE IN PREFRONTAL CORTEX IN RATS Behavioural Pharmacology. 16: S57. DOI: 10.1097/00008877-200509001-00181  0.359
2004 Neugebauer NM, Cunningham ST, Zhu J, Bryant RI, Middleton LS, Dwoskin LP. Effects of environmental enrichment on behavior and dopamine transporter function in medial prefrontal cortex in adult rats prenatally treated with cocaine. Brain Research. Developmental Brain Research. 153: 213-23. PMID 15527889 DOI: 10.1016/J.Devbrainres.2004.09.001  0.452
2004 Harrod SB, Dwoskin LP, Bardo MT. Lobeline produces conditioned taste avoidance in rats. Pharmacology, Biochemistry, and Behavior. 78: 1-5. PMID 15159128 DOI: 10.1016/J.Pbb.2004.01.011  0.347
2004 Miller DK, Crooks PA, Zheng G, Grinevich VP, Norrholm SD, Dwoskin LP. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. The Journal of Pharmacology and Experimental Therapeutics. 310: 1035-45. PMID 15121762 DOI: 10.1124/Jpet.104.068098  0.698
2004 Crooks PA, Ayers JT, Xu R, Sumithran SP, Grinevich VP, Wilkins LH, Deaciuc AG, Allen DD, Dwoskin LP. Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorganic & Medicinal Chemistry Letters. 14: 1869-74. PMID 15050618 DOI: 10.1016/J.Bmcl.2003.10.074  0.805
2004 Dwoskin LP, Sumithran SP, Zhu J, Deaciuc AG, Ayers JT, Crooks PA. Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents. Bioorganic & Medicinal Chemistry Letters. 14: 1863-7. PMID 15050617 DOI: 10.1016/J.Bmcl.2003.10.073  0.526
2004 Zhu J, Green T, Bardo MT, Dwoskin LP. Environmental enrichment enhances sensitization to GBR 12935-induced activity and decreases dopamine transporter function in the medial prefrontal cortex. Behavioural Brain Research. 148: 107-17. PMID 14684252 DOI: 10.1016/S0166-4328(03)00190-6  0.511
2004 Middleton LS, Cass WA, Dwoskin LP. Nicotinic receptor modulation of dopamine transporter function in rat striatum and medial prefrontal cortex. The Journal of Pharmacology and Experimental Therapeutics. 308: 367-77. PMID 14563785 DOI: 10.1124/Jpet.103.055335  0.727
2003 Rauhut AS, Neugebauer N, Dwoskin LP, Bardo MT. Effect of bupropion on nicotine self-administration in rats. Psychopharmacology. 169: 1-9. PMID 12811464 DOI: 10.1007/S00213-003-1450-X  0.446
2003 Grinevich VP, Crooks PA, Sumithran SP, Haubner AJ, Ayers JT, Dwoskin LP. N-n-alkylpyridinium analogs, a novel class of nicotinic receptor antagonists: selective inhibition of nicotine-evoked [3H] dopamine overflow from superfused rat striatal slices. The Journal of Pharmacology and Experimental Therapeutics. 306: 1011-20. PMID 12766255 DOI: 10.1124/jpet.103.051789  0.364
2003 Allen DD, Lockman PR, Roder KE, Dwoskin LP, Crooks PA. Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter. The Journal of Pharmacology and Experimental Therapeutics. 304: 1268-74. PMID 12604705 DOI: 10.1124/Jpet.102.045856  0.417
2003 Wilkins LH, Grinevich VP, Ayers JT, Crooks PA, Dwoskin LP. N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* and alpha7* neuronal nicotinic receptors. The Journal of Pharmacology and Experimental Therapeutics. 304: 400-10. PMID 12490617 DOI: 10.1124/Jpet.102.043349  0.798
2003 Miller DK, Harrod SB, Green TA, Wong MY, Bardo MT, Dwoskin LP. Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats. Pharmacology, Biochemistry, and Behavior. 74: 279-86. PMID 12479946 DOI: 10.1016/S0091-3057(02)00996-6  0.49
2003 Chen J, Norrholm S, Dwoskin LP, Crooks PA, Bai D. N,N-disubstituted piperazines: synthesis and affinities at alpha4beta2(*) and alpha7(*) neuronal nicotinic acetylcholine receptors. Bioorganic & Medicinal Chemistry Letters. 13: 97-100. PMID 12467625 DOI: 10.1016/S0960-894X(02)00849-1  0.669
2003 Harrod SB, Dwoskin LP, Green TA, Gehrke BJ, Bardo MT. Lobeline does not serve as a reinforcer in rats. Psychopharmacology. 165: 397-404. PMID 12459929 DOI: 10.1007/S00213-002-1289-6  0.36
2003 Zhu J, Crooks PA, Ayers JT, Sumithran SP, Dwoskin LP. N-n-Alkylnicotinium and N-n-Alkylpyridinium Analogs Inhibit the Dopamine Transporter: Selectivity as Nicotinic Receptor Antagonists Drug Development Research. 60: 270-284. DOI: 10.1002/Ddr.10328  0.553
2002 Rauhut AS, Mullins SN, Dwoskin LP, Bardo MT. Reboxetine: attenuation of intravenous nicotine self-administration in rats. The Journal of Pharmacology and Experimental Therapeutics. 303: 664-72. PMID 12388649 DOI: 10.1124/Jpet.303.2.664  0.45
2002 Green TA, Brown RW, Phillips SB, Dwoskin LP, Bardo MT. Locomotor stimulant effects of nornicotine: role of dopamine. Pharmacology, Biochemistry, and Behavior. 74: 87-94. PMID 12376155 DOI: 10.1016/S0091-3057(02)00960-7  0.473
2002 Ayers JT, Dwoskin LP, Deaciuc AG, Grinevich VP, Zhu J, Crooks PA. bis-Azaaromatic quaternary ammonium analogues: ligands for alpha4beta2* and alpha7* subtypes of neuronal nicotinic receptors. Bioorganic & Medicinal Chemistry Letters. 12: 3067-71. PMID 12372503 DOI: 10.1016/S0960-894X(02)00687-X  0.527
2002 Miller DK, Sumithran SP, Dwoskin LP. Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. The Journal of Pharmacology and Experimental Therapeutics. 302: 1113-22. PMID 12183670 DOI: 10.1124/Jpet.102.033852  0.508
2002 Miller DK, Wong EH, Chesnut MD, Dwoskin LP. Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. The Journal of Pharmacology and Experimental Therapeutics. 302: 687-95. PMID 12130733 DOI: 10.1124/Jpet.302.2.687  0.496
2002 Wilkins LH, Haubner A, Ayers JT, Crooks PA, Dwoskin LP. N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonist: inhibition of S(-)-nicotine-evoked [(3)H]dopamine overflow from superfused rat striatal slices. The Journal of Pharmacology and Experimental Therapeutics. 301: 1088-96. PMID 12023541 DOI: 10.1124/Jpet.301.3.1088  0.787
2002 Maragos WF, Zhu J, Chesnut MD, Dwoskin LP. Mitochondrial toxin inhibition of [(3)H]dopamine uptake into rat striatal synaptosomes. Biochemical Pharmacology. 63: 1499-505. PMID 11996892 DOI: 10.1016/S0006-2952(02)00910-3  0.494
2002 Dwoskin LP, Crooks PA. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochemical Pharmacology. 63: 89-98. PMID 11841781 DOI: 10.1016/S0006-2952(01)00899-1  0.538
2002 Xu R, Dwoskin LP, Grinevich V, Sumithran SP, Crooks PA. Synthesis and evaluation of conformationally restricted pyridino N-alkylated nicotine analogs as nicotinic acetylcholine receptor antagonists Drug Development Research. 55: 173-186. DOI: 10.1002/Ddr.10049  0.495
2001 Dwoskin LP, Teng LH, Crooks PA. Nornicotine, a nicotine metabolite and tobacco alkaloid: desensitization of nicotinic receptor-stimulated dopamine release from rat striatum. European Journal of Pharmacology. 428: 69-79. PMID 11779039 DOI: 10.1016/S0014-2999(01)01283-3  0.482
2001 Green TA, Crooks PA, Bardo MT, Dwoskin LP. Contributory role for nornicotine in nicotine neuropharmacology: nornicotine-evoked [3H]dopamine overflow from rat nucleus accumbens slices. Biochemical Pharmacology. 62: 1597-603. PMID 11755112 DOI: 10.1016/S0006-2952(01)00838-3  0.528
2001 Truong A, Xing X, Forsayeth JR, Dwoskin LP, Crooks PA, Cohen BN. Pharmacological differences between immunoisolated native brain and heterologously expressed rat alpha4beta2 nicotinic receptors. Brain Research. Molecular Brain Research. 96: 68-76. PMID 11731010 DOI: 10.1016/S0169-328X(01)00268-6  0.395
2001 Miller DK, Wilkins LH, Bardo MT, Crooks PA, Dwoskin LP. Once weekly administration of nicotine produces long-lasting locomotor sensitization in rats via a nicotinic receptor-mediated mechanism. Psychopharmacology. 156: 469-76. PMID 11498725 DOI: 10.1007/S002130100747  0.782
2001 Xu R, Dwoskin LP, Grinevich VP, Deaciuc G, Crooks PA. Neuronal nicotinic acetylcholine receptor binding affinities of boron-containing nicotine analogues. Bioorganic & Medicinal Chemistry Letters. 11: 1245-8. PMID 11354387 DOI: 10.1016/S0960-894X(01)00193-7  0.442
2001 Butt CM, Pauly JR, Wilkins LH, Dwoskin LP, Debski EA. Pharmacology, distribution and development of muscarinic acetylcholine receptor subtypes in the optic tectum of Rana pipiens. Neuroscience. 104: 161-79. PMID 11311540 DOI: 10.1016/S0306-4522(01)00048-3  0.745
2000 Green TA, Phillips SB, Crooks PA, Dwoskin LP, Bardo MT. Nornicotine pretreatment decreases intravenous nicotine self-administration in rats. Psychopharmacology. 152: 289-94. PMID 11105939 DOI: 10.1007/S002130000524  0.425
2000 Miller DK, Crooks PA, Dwoskin LP. Lobeline inhibits nicotine-evoked [(3)H]dopamine overflow from rat striatal slices and nicotine-evoked (86)Rb(+) efflux from thalamic synaptosomes. Neuropharmacology. 39: 2654-62. PMID 11044735 DOI: 10.1016/S0028-3908(00)00140-4  0.5
2000 Dwoskin LP, Xu R, Ayers JT, Crooks PA. Recent developments in neuronal nicotinic acetylcholine receptor antagonists Expert Opinion On Therapeutic Patents. 10: 1561-1581. DOI: 10.1517/13543776.10.10.1561  0.382
1999 Maragos WF, Jakel RJ, Chesnut MD, Geddes JW, Dwoskin LP. Does dopamine contribute to striatal damage caused by impaired mitochondrial function? Annals of the New York Academy of Sciences. 893: 345-9. PMID 10672263 DOI: 10.1111/J.1749-6632.1999.Tb07851.X  0.398
1999 Shafaee N, Houng M, Truong A, Viseshakul N, Figl A, Sandhu S, Forsayeth JR, Dwoskin LP, Crooks PA, Cohen BN. Pharmacological similarities between native brain and heterologously expressed alpha4beta2 nicotinic receptors. British Journal of Pharmacology. 128: 1291-9. PMID 10578144 DOI: 10.1038/Sj.Bjp.0702900  0.393
1999 Bardo MT, Green TA, Crooks PA, Dwoskin LP. Nornicotine is self-administered intravenously by rats. Psychopharmacology. 146: 290-6. PMID 10541729 DOI: 10.1007/S002130051119  0.408
1999 Dwoskin LP, Crooks PA, Teng L, Green TA, Bardo MT. Acute and chronic effects of nornicotine on locomotor activity in rats: altered response to nicotine. Psychopharmacology. 145: 442-51. PMID 10460322 DOI: 10.1007/S002130051079  0.424
1999 Dwoskin LP, Wilkins LH, Pauly JR, Crooks PA. Development of a novel class of subtype-selective nicotinic receptor antagonist: pyridine-N-substituted nicotine analogs. Annals of the New York Academy of Sciences. 868: 617-9. PMID 10414342 DOI: 10.1111/J.1749-6632.1999.Tb11334.X  0.778
1999 King VL, Dwoskin LP, Cassis LA. Cold exposure regulates the norepinephrine uptake transporter in rat brown adipose tissue. The American Journal of Physiology. 276: R143-51. PMID 9887188 DOI: 10.1152/Ajpregu.1999.276.1.R143  0.357
1999 Bardo MT, Valone JM, Robinet PM, Shaw WB, Dwoskin LP. Environmental enrichment enhances the stimulant effect of intravenous amphetamine: Search for a cellular mechanism in the nucleus accumbens Psychobiology. 27: 292-299. DOI: 10.3758/Bf03332123  0.462
1998 Teng L, Crooks PA, Dwoskin LP. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. Journal of Neurochemistry. 71: 258-65. PMID 9648873 DOI: 10.1046/J.1471-4159.1998.71010258.X  0.457
1997 Bardo MT, Bevins RA, Klebaur JE, Crooks PA, Dwoskin LP. (-)-Nornicotine partially substitutes for (+)-amphetamine in a drug discrimination paradigm in rats. Pharmacology, Biochemistry, and Behavior. 58: 1083-7. PMID 9408217 DOI: 10.1016/S0091-3057(97)00303-1  0.353
1997 Teng L, Crooks PA, Buxton ST, Dwoskin LP. Nicotinic-receptor mediation of S(-)nornicotine-evoked -3H-overflow from rat striatal slices preloaded with -3H-dopamine. The Journal of Pharmacology and Experimental Therapeutics. 283: 778-87. PMID 9353398  0.409
1997 Crooks PA, Dwoskin LP. Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochemical Pharmacology. 54: 743-53. PMID 9353128 DOI: 10.1016/S0006-2952(97)00117-2  0.422
1997 Weed MR, Paul IA, Dwoskin LP, Moore SE, Woolverton WL. The relationship between reinforcing effects and in vitro effects of D1 agonists in monkeys. The Journal of Pharmacology and Experimental Therapeutics. 283: 29-38. PMID 9336305  0.318
1997 Teng L, Crooks PA, Sonsalla PK, Dwoskin LP. Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake. The Journal of Pharmacology and Experimental Therapeutics. 280: 1432-44. PMID 9067333  0.419
1995 Dwoskin LP, Teng L, Buxton ST, Ravard A, Deo N, Crooks PA. Minor alkaloids of tobacco release [3H]dopamine from superfused rat striatal slices. European Journal of Pharmacology. 276: 195-9. PMID 7781690 DOI: 10.1016/0014-2999(95)00077-X  0.444
1995 Bardo MT, Bowling SL, Rowlett JK, Manderscheid P, Buxton ST, Dwoskin LP. Environmental enrichment attenuates locomotor sensitization, but not in vitro dopamine release, induced by amphetamine. Pharmacology, Biochemistry, and Behavior. 51: 397-405. PMID 7667360 DOI: 10.1016/0091-3057(94)00413-D  0.43
1995 Crooks PA, Ravard A, Wilkins LH, Teng LH, Buxton ST, Dwoskin LP. Inhibition of nicotine-evoked [3H]dopamine release by pyridino N-substituted nicotine analogues: A new class of nicotinic antagonist Drug Development Research. 36: 91-102. DOI: 10.1002/Ddr.430360204  0.809
1994 Cassis LA, Dwoskin LP. Acute and chronic losartan administration: effect on angiotensin II content and modulation of [3H]norepinephrine release from rat interscapular brown adipose tissue. Journal of Neural Transmission. General Section. 98: 159-64. PMID 7734113 DOI: 10.1007/Bf01277019  0.355
1993 Dwoskin LP, Buxton ST, Jewell AL, Crooks PA. S(-)-nornicotine increases dopamine release in a calcium-dependent manner from superfused rat striatal slices. Journal of Neurochemistry. 60: 2167-74. PMID 8492124 DOI: 10.1111/J.1471-4159.1993.Tb03502.X  0.425
1992 Dwoskin LP, Leibee LL, Jewell AL, Fang ZX, Crooks PA. Inhibition of [3H]dopamine uptake into rat striatal slices by quaternary N-methylated nicotine metabolites. Life Sciences. 50: PL233-7. PMID 1593921 DOI: 10.1016/0024-3205(92)90533-U  0.444
1992 Dwoskin LP, Jewell AL, Buxton ST, Carney JM. Phencyclidine-induced desensitization of striatal dopamine release. Neuropharmacology. 31: 1033-9. PMID 1436385 DOI: 10.1016/0028-3908(92)90105-X  0.347
1992 Dwoskin LP, Jewell AL, Cassis LA. DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum. Naunyn-Schmiedeberg's Archives of Pharmacology. 345: 153-9. PMID 1314959 DOI: 10.1007/Bf00165730  0.435
1991 Cassis LA, Dwoskin LP. Presynaptic modulation of neurotransmitter release by endogenous angiotensin II in brown adipose tissue. Journal of Neural Transmission. Supplementum. 34: 129-37. PMID 1667868 DOI: 10.1007/978-3-7091-9175-0_17  0.358
1990 Peris J, Boyson SJ, Cass WA, Curella P, Dwoskin LP, Larson G, Lin LH, Yasuda RP, Zahniser NR. Persistence of neurochemical changes in dopamine systems after repeated cocaine administration. The Journal of Pharmacology and Experimental Therapeutics. 253: 38-44. PMID 2329520  0.79
1989 Dwoskin LP, Yasuda RP, Zahniser NR. Irreversible inhibition of rat striatal dopamine uptake induced by in vitro exposure to DSP4. Biochemical Pharmacology. 38: 549-51. PMID 2917012 DOI: 10.1016/0006-2952(89)90400-0  0.613
1989 Gerhardt GA, Dwoskin LP, Zahniser NR. Outflow and overflow of picogram levels of endogenous dopamine and DOPAC from rat striatal slices: improved methodology for studies of stimulus-evoked release and metabolism. Journal of Neuroscience Methods. 26: 217-27. PMID 2521916 DOI: 10.1016/0165-0270(89)90119-2  0.608
1988 Dwoskin LP, Peris J, Yasuda RP, Philpott K, Zahniser NR. Repeated cocaine administration results in supersensitivity of striatal D-2 dopamine autoreceptors to pergolide. Life Sciences. 42: 255-62. PMID 3275855 DOI: 10.1016/0024-3205(88)90634-0  0.732
1988 Zahniser NR, Peris J, Dwoskin LP, Curella P, Yasuda RP, O'Keefe L, Boyson SJ. Sensitization to cocaine in the nigrostriatal dopamine system. Nida Research Monograph. 88: 55-77. PMID 3145458  0.716
1988 Peris J, Dwoskin LP, Zahniser NR. Biphasic modulation of evoked [3H]D-aspartate release by D-2 dopamine receptors in rat striatal slices. Synapse (New York, N.Y.). 2: 450-6. PMID 2973144 DOI: 10.1002/syn.890020413  0.731
1986 Dwoskin LP, Zahniser NR. Robust modulation of [3H]dopamine release from rat striatal slices by D-2 dopamine receptors. The Journal of Pharmacology and Experimental Therapeutics. 239: 442-53. PMID 3772803  0.618
Show low-probability matches.